Liver Cancer Trial, Recruiting NCT05375370 Sponsor: University Hospital, Rouen Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT05375370
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by a special type of CT scan or MRI scan showing specific patterns of blood flow in the liver
  • You have been diagnosed with liver cancer confirmed by a tissue biopsy (if the scan results were not clear enough to make a diagnosis)
  • You are scheduled to have surgery to remove part of your liver, or a procedure that uses heat to destroy the tumor (radiofrequency ablation)
  • Your treatment plan has been reviewed and approved by a specialist cancer team
  • You have read and understood the information provided about the trial and signed a form agreeing to take part
  • You are receiving follow-up care at Charles Nicolle University Hospital in Rouen

Who may not be able to join:

  • You currently have another type of active cancer or a blood cancer
  • You have a medical reason that means surgery is not safe for you
  • You are not registered with the French social security system
  • You are currently pregnant, have recently given birth, or are breastfeeding
  • You are under any form of legal protection or guardianship (such as a court-appointed guardian or legal representative managing your affairs)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Edouard ROUSSEL, MD, University Hospital, Rouen

Phone: +3323288

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Rouen
Registry
ClinicalTrials.gov
Start date
4 August 2022
Est. completion
1 February 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Change in tcNA dosage between baseline and 6 Months; Change in tcDNA dosage between baseline and 3 Months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov